Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Grubert

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumorsM M Henke, H Richly, A Drescher, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2003
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumorsH Richly, P Kupsch, K Passage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trialH Richly, B Schultheis, I A Adamietz, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 16, 2004
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancerH Richly, P Kupsch, K Passage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumorsM M Henke, H Richly, A Drescher, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2003
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumorsH Richly, P Kupsch, K Passage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trialH Richly, B Schultheis, I A Adamietz, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 16, 2004
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancerH Richly, P Kupsch, K Passage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.
Pageof 2